Jay Schmelter (RiverVest)

March 25, 2021 07:17 AM EDT

RiverVest off to the races with $275M to invest in early-stage biotech

Nicole DeFeudis

Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

Revolution’s KRAS drugs appear competitive in several lung cancer settings

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges